

Daniel M. Anderson, MD, MPH

Department of Hematology/Oncology, Regions Hospital
Assistant Professor, Division of Hematology/Oncology/Transplantation, University of Minnesota
Mail Stop 11503F 640 Jackson Street, St. Paul, MN 55101
Phone: 651-254-2299
Fax: 651-254-3470
Daniel.M.Anderson@HealthPartners.com

Current Position:

2003– present Staff Physician - Oncology/Hematology
Regions Hospital, St. Paul, MN

Academic Appointment:

2003 – present Assistant Professor of Medicine, Division of Hematology, Oncology and
Transplantation, University of Minnesota Medical School, Minneapolis, MN

Professional Experience:

2016 – Present Principal Investigator, Metro-Minnesota Community Oncology Research
Consortium

2014 – 2016 Associate Principal Investigator, Metro Minnesota NCORP

2009 – 2014 Associate Principal Investigator, Metro Minnesota CCOP

2007 – 2009 Principal Investigator, MN CGOP, Minneapolis, MN

Education:

1995 – 2001 M.P.H., Epidemiology University of Minnesota School of Public Health
Minneapolis, MN

1992 – 1997 M.D., University of Minnesota School of Medicine
Minneapolis, MN

1987 – 1991 B.A., Chemistry, St. Olaf College
Northfield, MN

Postgraduate Training and Fellowship:

- 2000 – 2003 Fellowship, Hematology/Oncology/Transplantation
University of Minnesota, Minneapolis, MN
- 1997 – 2000 Residency, Internal Medicine
Hennepin County Medical Center, Minneapolis, MN

Licenses and Certifications:

- Current Medical License – Minnesota Expires: 12/31/2020
Wisconsin Expires: 10/31/2021
- American Board of Internal Medicine – Hematology; Expires: 11/2023
- American Board of Internal Medicine – Medical Oncology; Expires: 11/2024

Professional Memberships and Research Affiliations:

- 2000 – present - American Society of Hematology
- 2000 – present - American Society of Clinical Oncology
- 2003 – present - National Cancer Institute
- 2003 – present – ECOG/ACRIN
- 2003 – present – NSABP/NRG
- 2003 – present – North Central Cancer Treatment Group (NCCTG)/Alliance for Clinical Trials in Oncology
- 2005 – present – Mayo Clinic Cancer Research Consortium/ACCRU
- 2010 – 2013 – NCCTG Audit Committee
- 2011 – present – Alliance for Clinical Trials Community Oncology/Clinical Outcomes Committees
- 2013 – present – Alliance for Clinical Trials in Oncology Board of Directors
- 2016 – present – Alliance for Clinical Trials in Oncology Service Enhancement Task Force
- 2016 – present – Principal Investigator, Metro Minnesota Community Oncology Research Consortium

2016– present – Alliance for Clinical Trials in Oncology Community Oncology Committee Co-Chair

2018 Selection Committee Alliance for Clinical Trials in Oncology Group Chair

Awards and Recognition:

2012-2019 – Top Doctor, Minneapolis St. Paul Magazine

2015 – Panel Participant, “Living Beyond Cancer”. Twin Cities Public Television Program

2014 – Profiled in “American Heart” a documentary film about medical care of immigrants to Minnesota

2009 – Regions Hospital Interpreter’s Award for Excellent Care of International Patients

2005, 2006 – Minnesota CGOP Top Investigator

2003 – ASCO/AACR Methods in Clinical Cancer Research Participant

1996 – Hawley Research Award (Epidemiology)

Selected Publications and Presentations:

Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, **Anderson DM**, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. *Cancer*. 2019 Nov 1;125(21):3790-3800

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. *Ann Oncol*. 2018 Oct 1;29(10):2150

Tanios S, Bekaii-Saab, Fang-Shu Ou, **Daniel M. Anderson**, et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) An ACCRU Network study. *Journal of Clinical Oncology* 36, no. 4_suppl (February 1 2018) 611-611 [Abstract]

Nancy L. Bartlett, MD, Betsy R. LaPlant, MS, Jing Qi, MD, PhD, Stephen M. Ansell, MD, PhD, John G. Kuruvilla, MD, Craig B. Reeder, MD, Lim S. Thye, MD, **Daniel M. Anderson, MD, MPH**, Charles Erlichman, MD and Barry A. Siegel, MD. Single-agent ibrutinib in relapsed or refractory

follicular lymphoma: a phase 2 consortium trial. *Blood* 2018 Jan 11;131(2):182-190; San Francisco, California. Abstract 800. [Manuscript]

Pamala A. Pawloski, PHARM.D.; Heather Kehn, BS, RN, MPH; **Daniel M. Anderson, MD.** The financial toll of cancer therapy. *Minnesota Medicine* August 2017; 30-31. [Article]

Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Irfan Firdaus, Philip Agop Philip, Allen Lee Cohn, Nancy Lewis, **Daniel M. Anderson**, Edward Arrowsmith, Jonathan D. Schwartz, Yihuan Xu, Minori Koshiji, Steven R. Alberts, Zev A. Wainberg. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 4004) [Abstract]

Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, **Anderson DM**, Mattar BI, Moore DF Jr, Nikcevic D, Loprinzi CL. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. *Am J Hematol.* 2015 Oct;90(10):877-81. [Manuscript]

Anderson DM. Challenges Facing Community Cancer Investigators. April 2014 [Oral presentation to the Alliance for Clinical Trials Board of Directors]

Haeseong Park, Rui Qin, Thomas J. Smith, Pamela J. Atherton, Debra L. Barton, Keren Sturtz, Shaker R. Dakhil, **Daniel M. Anderson** et al. NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. *Menopause* November 24, Epub ahead of print. [Manuscript]

Debra L. Barton, Jeff A. Sloan, Lynne T Shuster, Paula Gill, James D. Bearden, David B Johnson, Philip J. Stella, Shelby A. Terstriep, Fauzia N. Rana, **Daniel M. Anderson**, Charles L. Loprinzi Impact of vaginal dehydroepiandrosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance). *J Clin Oncol* 32:5s, 2014 (suppl; abstr 9507) [Abstract]

Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, **Anderson D**, et al. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. *J Thorac Oncol.* 2014 Aug;9(8):1146-53. [Manuscript]

Tan WW, Steen PS, Anderson DB, **Anderson DM**, et al. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group trial. *Annals of Oncology* 2013 Oct;24(10):2548-54 [Manuscript]

Demel KC, Jahagirdar BN, **Anderson DM**, et al Psychological and spiritual well-being of breast cancer survivors in a community-based cancer survivorship clinic. *J Clin Oncol* 28; 2010 (suppl; abstr e19673) [Abstract]

Tan WW, Hillman DW, Salim M, Northfelt D, **Anderson DM**, et al. N0332 Phase II Trial of Weekly Irinotecan Hydrochloride and Docetaxel in Refractory Metastatic Breast Cancer: a North Central Cancer Treatment Group (NCCTG) Trial. *Annals of Oncology*: 2010 Mar;21(3):493-7 [Manuscript]

Anderson DM, Rolnick SJ, Jackson J, Amundson J, Asche SE, Loes LM. Impact of chemotherapy in women with metastatic breast cancer diagnosed 1990-2003. *Clin Breast Cancer*. 2007 Oct;7(10):801-3. [Manuscript]

Anderson DM, Rennie KM, Ziegler RS, Neglia JP, Robison LR, Gurney JG. Medical and Neurocognitive Late Effects Among Survivors of Childhood Central Nervous System Tumors. *Cancer* 2001; 92 (10): 2709 [Manuscript]

Anderson DM, Defor T, Weisdorf DJ. Allogenic Related Donor Peripheral Blood Vs. Bone Marrow Transplants: A Comparative Analysis of Major Complications. 12/2001. [Abstract and poster presentation at the American Society of Hematology National Meeting]

Anderson DM, Jackson J, Butani A, Asche S, Rolnick C. Statin Use Is Associated With a Reduced Risk of Colon Cancer Recurrence. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4114 [Abstract and poster presentation at the American Society of Clinical Oncology Meeting]

Anderson D, Defor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D. A Comparison of Related Donor Peripheral Blood and Bone Marrow Transplants: Importance of Late-Onset Chronic Graft-Versus-Host Disease and Infections. *Biol Blood Marrow Transplant*. 2003 Jan; 9(1): 52-9. [Manuscript]

Wong L, Zhou J, **Anderson D**, Kratzke RA. Inactivation of p16INK4a Expression in Malignant Mesothelioma By Methylation. *Lung Cancer*. 2002 Nov; 38 (2):131-6 [Manuscript]

Anderson DM, Weisdorf DJ. Blood vs. Marrow Allogeneic Stem Cell Transplantation. In Rowe JM, Lazarus HM, and Carella AM (eds). Handbook of Bone Marrow Transplantation. 2001 [Book Chapter]